1. Home
  2. DOMO vs VRCA Comparison

DOMO vs VRCA Comparison

Compare DOMO & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Domo Inc. Class B

DOMO

Domo Inc. Class B

HOLD

Current Price

$2.51

Market Cap

171.6M

Sector

Technology

ML Signal

HOLD

Logo Verrica Pharmaceuticals Inc.

VRCA

Verrica Pharmaceuticals Inc.

HOLD

Current Price

$5.85

Market Cap

137.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DOMO
VRCA
Founded
2010
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
171.6M
137.3M
IPO Year
2018
2018

Fundamental Metrics

Financial Performance
Metric
DOMO
VRCA
Price
$2.51
$5.85
Analyst Decision
Buy
Buy
Analyst Count
9
2
Target Price
$10.28
$17.00
AVG Volume (30 Days)
1.7M
29.4K
Earning Date
05-20-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
31.92
N/A
EPS
N/A
N/A
Revenue
$318,857,000.00
$35,577,000.00
Revenue This Year
$3.41
N/A
Revenue Next Year
$4.72
$94.44
P/E Ratio
N/A
N/A
Revenue Growth
0.57
370.22
52 Week Low
$1.84
$0.52
52 Week High
$18.49
$9.82

Technical Indicators

Market Signals
Indicator
DOMO
VRCA
Relative Strength Index (RSI) 38.61 43.26
Support Level $2.39 $5.32
Resistance Level $4.07 $6.48
Average True Range (ATR) 0.39 0.48
MACD -0.16 -0.01
Stochastic Oscillator 23.68 8.33

Price Performance

Historical Comparison
DOMO
VRCA

About DOMO Domo Inc. Class B

Domo Inc provides a cloud-based platform that digitally connects all the data, systems, and people in an organization, giving them access to real-time data and insights and allowing them to manage their business from their smartphones. The company offers a platform to its customers as a subscription-based service. Users receive notifications on any device and immediately act on the invitation, after which the system can write back to the original system of record. The company derives revenue from subscriptions to its cloud-based platform and professional services.

About VRCA Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.

Share on Social Networks: